A monthly recap on major events in indian pharmacuetical industry, which saw numerous policy reforms, innovation, drug approvals, and disease control methods
India has earned global recognition for its India pharma industry, but the next phase of growth could depend on a major shift.
Aurobindo Pharma's Lannett Acquisition has officially entered a new phase with the successful completion of its USD 250 million buyout of US-based Lannett Company.
Aarogya Setu 2.0 is no longer just a COVID-19 app. The Centre has launched a revamped version of the platform with several new features that bring PM-JAY Wallet, Digital Health Records, and other healthcare services under one roof.
The Union Ministry of Health and Family Welfare has announced a single platform for all medicine-related information, which creates a space that users can easily access for domestic generic medicines through the respective generic name and brand name
The Ebola crisis in DR Congo has entered a more dangerous phase, with the Ebola outbreak now spreading to a fourth province.
India's Pharma Exports are entering a new phase as drugmakers expand beyond their biggest market, the US, to tap fresh opportunities in Brazil.
Alembic marks another milestone in securing approval from the USFDA for Dapsone Gel, which is a treatment for acne vulgaris, a skin disorder. Alembic marks this as an achievement, which turns them on to the US market
The global diabetes clinical trials market is on a steady upward trajectory, projected to grow from USD 5.45 billion in 2026 to USD 10.02 billion by 2034, at a CAGR of 7.9 percent, according to a comprehensive new industry analysis.
India has taken another step to tackle Anaemia by expanding its flagship Anaemia Mukt Bharat programme.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")